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Background: Management of advanced laryngeal cancer is complex and ideal strategy is yet to be defined. This
study evaluates the experience of a single head and neck oncologic centre in the management of T4 laryngeal
cancer.
Methods: Retrospective assessment of cases primarily treated for T4a squamous cell carcinoma of the larynx,
between 1980 and 2007, at a tertiary referral center.
Results: A total of 384 cases were studied. Five-year disease specific survival was 56.2% and local control 87.4%.
Regional and distal control estimates were 90.3% and 88.3% respectively. Prognosis was significantly superior for
cases treated with primary surgery compared to cases solely managed with non-surgical modalities. Positive surgical
margins and regional disease worsened prognosis.
Conclusion: This study suggests that primary surgery remains a key element in the treatment of advanced
laryngeal cancer. The need for well-designed, prospective, randomised studies in order to further evaluate the
remaining role of primary surgery in the modern management of locally advanced laryngeal lesions is emphasized.
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Laryngeal cancer represents one of the most common
head and neck malignancies, accounting approximately
for 20% of all cases. The vast majority of tumors are squa-
mous cell carcinomas [1,2]. Up to 40% of patients present
with advanced disease [3]. Due to the important physio-
logic functions of the larynx, advanced laryngeal lesions
are associated with significant morbidity and mortality for
the patient and increased financial costs for society [4,5].
Management of advanced laryngeal cancer is complex
and the ideal strategy is yet to be defined [6]. Treatment
has so far included total laryngectomy (TL), alone or with
neck dissection (ND), radiotherapy (RT) alone, TL followed
by RT, and combined chemotherapy and RT (CRT) [6,7].
TL followed by adjuvant RT has been widely considered
the standard management option for many years [8].* Correspondence: heinrich.iro@uk-erlangen.de
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reproduction in any medium, provided the orHowever, a shift toward organ-preservation strategies with
the use of primary CRT has been recently noted [8,9].
In order to define the ideal management, different as-
pects must be considered. These include oncologic out-
comes, functional results and morbidity, as well as financial
costs. Currently, a lack of large-scale prospective studies
comparing different management options for advanced la-
ryngeal cancer is noted. In this context, non-randomized
data may offer some basis for treatment decision-making.
This study aims to evaluate the experience of a single head
and neck oncology center in the management of T4 laryn-
geal cancer.Methods
A retrospective study was conducted at an academic
tertiary referral center (Department of Otorhinolaryn-
gology, Head and Neck Surgery, University of Erlangen-
Nuremberg Medical School, Erlangen, Germany). Relevant
approval from the institutional review board of the hospital
was obtained. The files of all patients primarily treated for
T4a category carcinoma of the larynx, between 1980 andral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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disease at the time of diagnosis, and histology other than
squamous cell carcinoma, as well as patients with second
primary tumors at the time of diagnosis, were excluded
from the study.
All pathology reports were reviewed and staging was
conducted in accord with the 2010 American Joint Com-
mittee on Cancer (AJCC) and Union Internationale Centre
Contre Cancer (UICC) classification [10]. T4a cases of la-
ryngeal cancer include any supraglottic, glottic, or subglot-
tic lesions that invade through the thyroid cartilage, or
invade tissues beyond the larynx, e.g., trachea, soft tissues
of neck including deep/extrinsic muscle of tongue (genio-
glossus, hyoglossus, palatoglossus, and styloglossus), strap
muscles, thyroid, oesophagus. Tumors invading preverteb-
ral space, or mediastinal structures, or encase carotid ar-
tery, are considered T4b and were therefore excluded
from this study. Since T4 carcinomas had been subdivided
into T4a and T4b in 2002, the files of patients with T4 tu-
mors treated prior to this date were carefully re-assessed
to differentiate between T4a and T4b. Standard diagnostic
investigations reviewed included ultrasonography and
computed tomography. Magnetic resonance imaging was
also used in a few cases. The appropriate treatment modal-
ity had been decided by the interdisciplinary tumor board
in every case. Factors that mainly influenced the decision
included the operability of the tumor, general health status
and personal preference of each patient.
All patients were assessed for Disease Specific Sur-
vival (DSS) and Overall Survival (OS) as well as Local
Control (LC) rates, with respect to T classification, N clas-
sification, type of primary treatment, status of surgical
margins, and adjuvant therapy. Surgical margins were
evaluated from primary tumor pathology reports and con-
sidered as positive when characterized by the presence of
invasive carcinoma at the edge of resection on permanent
section pathology.
Five year DSS was defined using the time from the date
of diagnosis to death from the tumor or complications of
treatment. Time to LC or regional control (RC) was calcu-
lated from the date of initial diagnosis to the date of most
recent clinical review when local or regional recurrence
was confirmed. Local recurrence was defined as invasive
carcinoma developing after completion of initial treatment
at the anatomic site of the primary tumor. Regional and
distal recurrences were defined as the presence of the
same tumor in the regional lymph nodes or distant sites
respectively, after the completion of initial treatment. Cal-
culations of five-year overall and disease-specific survival,
local control and regional control were made with Kaplan-
Meier estimates and compared by the means of the log-
rank test. A p value of less than 0.05 was considered
significant. Statistical analysis was performed using SPSS
Version 19 (SPSS In., Chicago IL, USA).Cases managed with surgery were additionally evaluated
for incidence of major complications. Unfortunately, no
data regarding complications of non-surgical modalities
were available for assessment. Major surgical complica-
tions were defined as those which necessitated prolonged
hospitalization, blood transfusion, additional surgery, or
admission to the intensive care unit. Pharyngeal function
was indirectly evaluated by assessing the incidence of per-
manent gastrostomies.
Results
A total of 384 cases that satisfied the inclusion criteria were
analyzed. Among these, 354 were men and 30 women, ap-
proximating a 12:1 men to women ratio. Mean age was 59
years, ranging from 31 to 91 years. Mean follow-up period
was 4.7 years (median 2.199, range 0.2-26.1). When classi-
fied in accord with anatomic location, 208 cases (54.1%)
were supraglottic carcinomas, 142 cases (36.9%) were glot-
tic, and 15 cases (4%) were subglottic; 19 additional cases
(5%) could not be further classified. In accord with path-
ology, 258 cases (67.1%) were classified as well differen-
tiated (grade I or II) and 103 cases (26.8%) as poorly
differentiated (grade III or IV). A detailed description of
demographics, tumor localization, N status, and histo-
logical differentiation, is presented in Table 1.
Five-year DSS was 56.2% overall in this series while LC
was 87.4%. Regional and distal control estimates were
90.3% and 88.3% respectively. Two major groups could be
defined in accord with management. One received radio-
therapy with or without chemotherapy as primary treat-
ment (CRT group) and if needed salvage surgery (63
cases). The other underwent primary surgery (321 cases)
with or without adjuvant CRT. Table 2 shows the detailed
treatment variation in the two groups. Although cases
were unevenly distributed among the different forms of
treatment, prognosis was found to differ significantly be-
tween the two groups. Patients treated with surgery and
CRT were found to have superior prognosis. DSS rate was
62.2% for the primary surgery group and 24.5% for the
CRT group (p < 0.001). OS rates were 41.1% and 16.7%
(p < 0.001) respectively. Kaplan-Meier analysis of DSS in
accord with primary treatment is presented in Figure 1.
Moreover, OS rates were 41.1% for the primary surgery
group and 16.7% for the CRT group (p < 0.001). On the
other hand, comparable results were found with regard to
LC as the former group achieved 87.6% and the latter
83.6% rates (p not interpretable).
Decision to perform surgery as primary treatment was
mainly based on local extent of disease, and general health
status as well as personal preference of each patient. TL
with some form of ND according to the status of the neck
was the surgical procedure typically performed. The ma-
jority of cases undergoing primary surgery (233/321) also
received adjuvant treatment consisting of radiotherapy










OP 88 53.9 31.1 81.7
OP + RT 199 62.6 42.0 88.8
OP + RCT 34 80.8* 64.3 93.5*
RT (+/- salvage surgery) 35 21.5 11.7 73.9*
RCT (+/- salvage
surgery)
28 28.8 23.1 94.7*
Total 384 56.2 37.2 87.4
OP: primary surgery only. OP + RCT: primary surgery plus adjuvant
radiotherapy. OP + RCT: primary surgery plus adjuvant chemoradiation. RT:
primary radiotherapy. RCT: primary radiochemotherapy. DSS: disease specific
survival. OS: overall survival. LC: local control.
*low number of cases.
Table 1 Detailed description of demographics, tumor
localization, histological differentiation, and N status of
all cases in this series




Sex Male 354 92.2
Female 30 7.8
Age (grouped) ≤59 194 50.5
>59 190 49.5




Tumor localization Supraglottic 208 54.2
Glottic 142 37.0
Subglottic 15 3.9
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are difficult to detect retrospectively, 88 cases were spared
from adjuvant treatment. Usual causes included refusal of
the patient, comorbitities, and death before application of
adjuvant therapy. Interestingly, oncologic results among
these two surgical subgroups were not found to differ sig-
nificantly. It is emphasized again that comparison is hin-
dered by the unequal distribution of cases among the two
subgroups. DSS and LC were 64.3% and 89.5% respectively
for the first subgroup, and 53.9% and 81.7% respectively
for the second subgroup (p = 0.074 for both DSS and LC).
According to pathology reports, negative surgical mar-
gins (R0 status) had been achieved in 278 out of 321
(86.6%) surgically treated cases in this series. Conversely,
27 (8.4%) cases had positive surgical margins (R + status)
at the end of surgical treatment. All of these cases later
received adjuvant treatment. For an additional 16 cases
R status could not be determined. Survival rates were
found to be superior for cases with R0 status compared
to R + status cases (DSS 64.2% versus 50.0% respect-
ively). However, R + status group was comparatively very
small thus limiting the statistical power of the log-rank
test. Kaplan-Meier analysis of DSS according to R status
is presented in Figure 2.
Patients that were not treated with primary surgery re-
ceived radiotherapy with or without chemotherapy. Se-
lection of the exact treatment scheme was individualized
according mainly to the extent of disease and the general
health status of each patient. Non-surgical treatment has
been affected by various changes in protocols as well as
technical developments that have been noted over the
years in this centre. For relatively recent cases, however,Figure 1 Kaplan-Meier analysis of disease specific survival (DSS)
in accord with primary treatment.
Figure 2 Kaplan-Meier analysis of disease specific survival (DSS)
in accord with status of surgical margins (R). R0: negative
surgical margins. R+: positive surgical margins.
Table 3 Detailed presentation of complications in cases
treated with primary surgery



















No specifications 2 0.6
Total 321
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therapy with a cumulative dose of 70-72 Gy (mean dose
60.71, median dose 60.7, range 26-80 Gy) using conven-
tional fractionation, plus concomitant cisplatinum-based
chemotherapy. Salvage operation was typically performed
8-12 weeks following completion of CRT in cases where
residual disease had been identified.
Clinical or histological evidence of regional disease was
found in 196 (51%) out of 384 cases at the time of initial
management. A detailed presentation of N status may be
found in Table 1. The presence of regional metastases af-
fected prognosis. DSS rates were 66% for N0 and 46.2%
for N + cases (p = 0.002). Similarly, OS rates were 44.9%
and 29.5% respectively (p = 0.001). In all cN0 cases under-
going surgery, bilateral selective dissection of levels II, III,
and IV was performed. From 144 cN0 cases, 116 under-
went elective ND and 35 proved to be pN+, giving an oc-
cult metastasis rate of 30.1%. In cases with known or
suspected neck metastases, a modified radical neck dissec-
tion was typically performed. Similar management was re-
served for cases in the CRT group that showed clinical
evidence of regional disease 8-12 weeks after primary
treatment.
Overall incidence of complications was 20.8% for cases
undergoing primary surgery (67/321 cases). Complica-
tions mainly included fistula formation, wound healing
problems, and bleeding. None of these complications
was fatal. A detailed presentation may be found in
Table 3. Pharyngeal functional results were satisfactory,
as evidenced by the very low rate of permanent gastros-
tomies (11/321 cases).Discussion
The larynx plays a fundamental role in human speech
and communication. This fact must always be given
consideration when a decision has to be made for the opti-
mal management of a laryngeal tumor. Organ-preservation
strategies, either surgical or non-surgical, have dominated
the treatment of early laryngeal lesions in recent years
[11,12]. A trend toward conservative management has also
been noted for locally advanced carcinomas [8,9]. TL is
not the only available treatment option for such lesions
anymore. Recent developments and newly integrated
strategies, including concomitant CRT (CCRT), induction
chemotherapy, and modern RT methods have reshaped
the field of advanced laryngeal cancer treatment [13-15].
Such a shift in management strategy aims at improved
clinical outcome, retention of function, and superior qual-
ity of life [9].
Among available organ-preservation modalities, platinum-
based CCRT has proven most effective and popular for
advanced lesions, showing high rates of laryngeal pre-
servation and satisfactory oncologic results [16,17]. Both
radiotherapy and chemotherapy, however, have been as-
sociated with severe adverse effects. Such effects locally
include dysphagia, xerostomia, trismus, mandibular radio-
necrosis, fibrosis, and pharyngeal strictures. Systemic ad-
verse effects may also appear and these include bone
marrow toxicity, infections, neuropathy, renal failure, nu-
tritional deficiencies, and fatigue. Severe late toxicity has
also been recently identified as an important issue associ-
ated with CCRT [18]. Additional consideration should be
given to the increased incidence of complications follow-
ing salvage surgery in cases previously treated with CCRT
protocols [19].
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grated in the primary management of advanced head and
neck cancer it becomes more apparent that organ preser-
vation does not necessarily lead to functional preservation.
In other words, simply preserving the larynx does not
guarantee its function [20]. Late functional issues following
CRT might involve voice as well as swallowing difficul-
ties and in numerous occasions necessitate a permanent
tracheostomy and/or gastrostomy. In fact, quality of life in
many individuals may end up to be much worse after
organ preservation treatment compared to cases that have
undergone TL and are able to eat normally and commu-
nicate sufficiently with the aid of a prosthesis or other
method [21].
Billroth is credited for performing the first TL for cancer
in 1873 and for many years this has been the standard of
treatment for advanced laryngeal cancer [8,22]. In many
areas, however, the application of TL as initial treatment
has decreased remarkably [8]. It is now mostly employed as
salvage treatment after failure of non-surgical management
strategies. Nevertheless, TL may still play an important role
as primary therapy for laryngeal cancer. The question
whether the most advanced laryngeal lesions with invasion
of cartilage are better served with initial non-surgical ther-
apy or TL still remains open. In fact, an advantage in prog-
nosis for surgery in such cases has been previously shown
and this remains the main option for management in many
areas of the world [23,24]. Moreover, in cases of unreliable
patients, or patients who might live in underserved areas,
or are not physically fit to undergo the ordeal of CCRT, or
even when cost issues are most important, surgery seems
to gain the upper hand [8].
In this study, one of the largest T4 laryngeal carcinoma
series available in the literature is presented. Between two
treatment groups where surgery was primarily applied or
not, differences in disease control and survival were noted
with the surgical group performing significantly better. As
expected, status of the neck on diagnosis and surgical
margins also affected survival. A low incidence of com-
plications was generally noted for TL and none of these
proved to be fatal. Unfortunately, no comparison between
complication rates in the surgical and non-surgical groups
could be made as complications in the latter had not been
documented.
The data presented here meet many of the limitations
inherent in retrospective studies. These limitations include
selection bias and use of non-standard treatments with
modifications made in radiotherapy and chemotherapy
protocols over the years. Moreover, the lack of data re-
garding complications and functional results for patients
managed with non-surgical treatment modalities makes
comparison between treatment strategies more difficult.
However, the aim of this study was by no means to prove
that one type of treatment, i.e. surgery, is superior to othermanagement modalities available today for advanced la-
ryngeal cancer. In fact primary surgery should not be
addressed as a single treatment option for T4 laryngeal
cancer but rather be included as the initial part of a com-
bined strategy that certainly includes radiotherapy and in
many situations chemotherapy as well. In the mind of the
authors, comparing complications and functional results
between primarily surgical and non-surgical treatment op-
tions, although valuable, is of secondary importance here.
More important is the motive to provide data supporting
a common notion among head and neck surgeons that
primary surgery remains a crucial part of T4 laryngeal
cancer treatment. This comes in contradiction with an-
other notion that has been recently introduced in the
literature pointing that CCRT is a valid option for T4 la-
ryngeal cancer and cartilage invasion should by no means
considered a contraindication for enrolment in CCRT pro-
tocols [25,26]. If nothing else, it becomes clear that well-
designed studies are necessary in order to provide solid
evidence regarding the best treatment strategy for ad-
vanced laryngeal cancer. In the mean time, and as long as
prospective randomized studies are generally lacking, data
such as that presented here may prove valuable during
treatment decision-making.Conclusion
In an era when non-surgical treatment modalities begin
to dominate the treatment of advanced laryngeal cancer,
this study suggests that surgery remains a key element
for successful management of T4 laryngeal lesions. The
need for well-designed prospective randomised studies
in order to reach safer conclusions is emphasized.
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